GlassScriptPhysician profile
Kathryn E Nielsen
NPI 1619416674
$5,288.50
in general payments reported to CMS, 2019-2025
40 companies · $818 in 2025
The $818 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $725 · 2023: $664 · 2024: $2,169 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470 · Travel and Lodging: $1,160 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.36 |
| Travel and Lodging | $1,160.07 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,497.12 | 2022-2024 | Minimed 780g, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $500.37 | 2021-2025 | |
| Lilly USA, LLC | $401.73 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $330.21 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $253.92 | 2021-2025 | Wegovy, Sogroya |
| Abbvie INC. | $246.52 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.53 | 2025 | Caplyta |
| Radius Health, INC. | $161.41 | 2021-2024 | Tymlos |
| Amgen INC. | $152.46 | 2022-2025 | Tepezza, Prolia, Evenity |
| Esperion Therapeutics, INC. | $140.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.14 | 2022-2025 | Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $98.81 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $93.23 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $88.90 | 2023-2024 | Omnipod |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $79.08 | 2021-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $76.44 | 2021-2023 | Lokelma |
| Ascendis Pharma Endocrinology INC | $73.27 | 2022-2023 | |
| Inspire Medical Systems, INC. | $60.37 | 2023-2025 | Inspire |
| Kyowa Kirin, INC. | $57.20 | 2023-2025 | Crysvita |
| Corcept Therapeutics | $55.02 | 2024-2025 | Korlym |
| Madrigal Pharmaceuticals | $49.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Pharmaceuticals, INC | $44.32 | 2021 | |
| Tolmar, INC. | $38.82 | 2025 | Fensolvi |
| Ultragenyx Pharmaceutical INC. | $38.72 | 2021-2022 | |
| Dexcom, INC. | $38.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.09 | 2021-2025 | |
| Ibsa Pharma INC. | $23.26 | 2021 | |
| Horizon Therapeutics Plc | $21.17 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.92 | 2022 | |
| Tandem Diabetes Care, INC. | $19.74 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amryt Pharma Holdings LTD | $18.90 | 2022 | |
| Eton Pharmaceuticals, INC. | $18.66 | 2024 | Alkindi |
| Pfizer INC. | $17.58 | 2023 | |
| Biomarin Pharmaceutical INC. | $16.46 | 2024 | Voxzogo 1.2mg |
| Eusa Pharma (US) LLC | $14.87 | 2022 | |
| Boston Scientific Corporation | $14.01 | 2025 | General - Pain Management |
| Nevro Corp. | $13.35 | 2021 | |
| Amarin Pharma, INC. | $13.32 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.93 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Nielsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.